Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Elizabeth Ravera

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient With MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition

Journal of Thoracic Oncology

English

Related publications

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy

Oncology

Pharmacology

2015

English

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology

English

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Clinical Cancer Research

Cancer Research

Oncology

2010

English

Mechanisms of Acquired Resistance to EGFR-tyrosine Kinase Inhibitor in Korean Patients With Lung Cancer

English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Cancer Research

Oncology

2017

English

Impressive Response to Tyrosine Kinase Inhibitors in a Patient With Respiratory Failure for EGFR -Mutated Metastatic Lung Cancer

Journal of Thoracic Oncology

English

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Elizabeth Ravera

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient With MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition

Related publications

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Mechanisms of Acquired Resistance to EGFR-tyrosine Kinase Inhibitor in Korean Patients With Lung Cancer

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Impressive Response to Tyrosine Kinase Inhibitors in a Patient With Respiratory Failure for EGFR -Mutated Metastatic Lung Cancer

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib